The Head of the Covid-19 National Vaccine Taskforce has said there will only be a modest impact to the rollout of the vaccination programme by a temporary reduction in supplies of the Pfizer BioNTech vaccine.
Professor Brian MacCraith said, “After a stressful day, it has been very relieving news to hear from Pfizer this evening that the proposed reduction will only apply to one week and that is this coming week.”
MacCraith said he was assured by the Chief Executive of Pfizer in a conference call this evening that the production of the vaccine will return to the normal schedule the following week, before being scaled up from the middle of next month.
He said, “There is additional good news that from 15th February onwards, there will be significant growth in the supplies coming in.”